Cargando…

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

BACKGROUND: Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to the same neoadjuvant chemo-radiotherapy (CR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curioni-Fontecedro, Alessandra, Perentes, Jean Yannis, Gelpke, Hans, Xyrafas, Alexandros, Bouchaab, Hasna, Mach, Nicolas, Matzinger, Oscar, Stojcheva, Nina, Frueh, Martin, Weder, Walter, Cathomas, Richard, Gargiulo, Piera, Bubendorf, Lukas, Pless, Miklos, Betticher, Daniel, Peters, Solange
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734655/ https://www.ncbi.nlm.nih.gov/pubmed/30988393 http://dx.doi.org/10.1038/s41416-019-0447-0

Ejemplares similares

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022)

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
por: König, D., et al.
Publicado: (2023)

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
por: Bratic Hench, Ivana, et al.
Publicado: (2019)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
por: Joerger, M., et al.
Publicado: (2021)

Is sleeve lobectomy safe after induction therapy?—a systematic review and meta-analysis
por: Chriqui, Louis-Emmanuel, et al.
Publicado: (2021)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma
por: Bergstrom, Jennifer, et al.
Publicado: (2015)

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
por: Panje, Cédric M., et al.
Publicado: (2019)

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
por: Joerger, Markus, et al.
Publicado: (2022)

LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
por: Joerger, M., et al.
Publicado: (2020)

A new era of oncology through artificial intelligence
por: Curioni-Fontecedro, Alessandra
Publicado: (2017)

Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
por: Amrein, M. A., et al.
Publicado: (2020)

Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
por: Hayoz, Stefanie, et al.
Publicado: (2023)

The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
por: Clough-Gorr, Kerri M, et al.
Publicado: (2013)

High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
por: Fehr, Martin, et al.
Publicado: (2020)

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
por: Mark, Michael, et al.
Publicado: (2019)

Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study
por: Rothschild, Sacha I., et al.
Publicado: (2019)

Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
por: Forster, Céline, et al.
Publicado: (2021)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
por: Lauk, Olivia, et al.
Publicado: (2020)

Ionic liquids IIIB
por: Rogers, Robin D, et al.
Publicado: (2005)

How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
por: Banna, Giuseppe, et al.
Publicado: (2020)

Reply to Authors
por: Banna, Giuseppe, et al.
Publicado: (2020)

Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
por: Grundmann, Eva, et al.
Publicado: (2023)

08.08.08, czyli najbardziej zagadkowy dzień roku
Publicado: (2008)

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
por: Vetter, Marcus, et al.
Publicado: (2022)

Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)
por: Ribi, Karin, et al.
Publicado: (2021)

Optical fiber telecommunications IIIB
Publicado: (1997)

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
por: Petrausch, Ulf, et al.
Publicado: (2023)

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
por: Gargiulo, Piera, et al.
Publicado: (2019)

Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer
por: Britschgi, Christian, et al.
Publicado: (2018)

In vitro cell culture of patient derived malignant pleural and peritoneal effusions for personalised drug screening
por: Wu, Cheng-Guang, et al.
Publicado: (2020)

Stereotactic lung reirradiation for local relapse: A case series
por: Kinj, Rémy, et al.
Publicado: (2021)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

An Uncommon Presentation of Mucopolysaccharidosis Type IIIb
por: REZAYI, Alireza, et al.
Publicado: (2019)

Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

True abscopal effect in a patient with metastatic non-small cell lung cancer
por: Vilinovszki, Oliver, et al.
Publicado: (2021)

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
por: Blum, David, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ghacufi6htopaq7vnvgriajr8e